Monomeric DAPTA Peptide Preparation for HIV Reservoir Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HAART therapies fail to effectively treat monocyte/macrophage viral reservoirs, leading to persistent HIV infection and treatment resistance, due to aggregation and loss of biological activity in peptide drugs like DAPTA and Peptide T, which reduces their potency and shelf-life.
Innovation Solution
Preparation of monomeric DAPTA and related peptides through methods that prevent aggregation, such as using fluorinated organic solvents and reconstitution techniques, to maintain biological activity and stability, thereby enhancing their antiviral potency and storage stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HAART therapies are used to treat HIV, then viral replication is suppressed in plasma, but monocyte/macrophage viral reservoirs persist and continue to shed infectious virus
Solution Approach 1:
The patent changes the chemical state of the peptide from aggregated to monomeric form through specific preparation methods involving fluorinated organic solvents and controlled reconstitution. This parameter change in peptide morphology enables the drug to effectively penetrate and treat monocyte/macrophage reservoirs that are resistant to conventional HAART therapies, while maintaining plasma viral suppression.
2Reliability
If peptide drugs like DAPTA and Peptide T are used to block CCR5, then viral entry is inhibited, but the peptides aggregate and lose biological activity
Solution Approach 1:
The patent applies preliminary action by performing peptide aggregation removal during the synthesis and purification process before the peptide reaches the patient. Specific steps include using fluorinated organic solvents during synthesis and implementing controlled reconstitution procedures that prevent aggregate formation, ensuring the peptide arrives at the target site in its active monomeric form.
Solution Approach 2:
The patent changes the physical state parameter of the peptide from aggregated to monomeric form through specific preparation methods. This involves using fluorinated organic solvents during synthesis and controlled reconstitution with aqueous solutions, which prevents aggregation and maintains biological activity, thereby resolving the contradiction between antiviral potency and compositional stability.
3Duration of action of stationary object
If peptide solutions are stored for extended periods, then shelf-life is extended, but aggregation occurs and biological activity is lost
Solution Approach 1:
The patent applies preliminary action by removing aggregation-prone species during the synthesis and purification process before storage. This includes using fluorinated organic solvents during synthesis and implementing controlled reconstitution procedures that prevent aggregate formation, ensuring the peptide remains stable and active during extended storage periods.
Solution Approach 2:
The patent changes the storage parameter by formulating the peptide in a monomeric state using fluorinated organic solvents during synthesis and controlled reconstitution. This creates a stable formulation that prevents aggregation during storage, maintaining biological activity throughout the shelf-life while extending the duration the product remains effective.
4Device complexity
If monocyte/macrophage reservoirs are not treated, then current HAART can be simplified, but virus reemergence occurs upon cessation of therapy
Solution Approach 1:
The patent changes the peptide formulation from aggregated to monomeric form, enhancing its ability to penetrate and treat monocyte/macrophage reservoirs. This parameter change enables the peptide to effectively eliminate the viral reservoir that persists under conventional HAART, thereby preventing virus reemergence upon therapy cessation and improving treatment durability without significantly increasing complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified peptide compositions demonstrate 100-1000 fold increased potency in inhibiting HIV replication in monocyte/macrophages, reducing CCR5 expression, and preventing neuronal apoptosis, offering a more effective treatment for persistent viral reservoirs and AIDS-related dementia.
Implementation Method 1
removing aggregate seeds that form fibrils and lose bioactivity by treating with a fluorinated organic solvent
Data Source
AI summary
Residual HIV-1 replication reemerges after intensive therapy from location or locations in the body called the drug resistant non-plasma viral reservoir. Methods are disclosed of treating HIV by inhibiting or blocking this reemergence with various monomeric therapeutic peptide compositions including monomeric DAPTA prepared in least 80% trifluoroethanol, with vigorous shaking for at least about 24 hours at about 37° C.